cancer or cancer-associated complications and age-related ophthalmologic diseases
WUHAN YZY BIOPHARMA CO., LTD. was established in 2010 and is a biotechnology company dedicated to the development of bispecific antibody (BsAb) therapies. The Company focuses on therapeutic areas with significant market potential, including oncology and its complications, age-related ophthalmologic diseases and autoimmune diseases, and has proactively established proprietary innovative technology platforms, including YBODY®, Check-BODY and Nano- YBODY®. Leveraging its strong research and development capabilities, the Company has established a pipeline of multiple drug candidates, including its core product M701, of which four are currently at the clinical development stage and two are at the preclinical research stage.
With respect to its core product, M701, a bispecific antibody targeting EpCAM/CD3 independently developed by the Company, has made significant clinical progress. To date, the new drug application (NDA) for M701 for the treatment of malignant ascites has been accepted by the China National Medical Products Administration, while the investigational new drug (IND) application for M701 for the treatment of malignant pleural effusion has been approved by the U.S. Food and Drug Administration (FDA). In addition, data from two important clinical studies of M701 were selected for presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), further validating the clinical value and international potential of the product.
The Company continues to deepen its external technology collaborations. By entering into licensing cooperation agreements with leading companies in the industry, the Company has steadily advanced its research and development services and milestone recognition, effectively optimising its research and development expenditure structure. The Company will continue to uphold its mission of “discover and develop innovative drugs to improve the health and well-being of patients”, accelerate the commercialisation of its core pipeline and strive to provide high-quality innovative treatment solutions to patients worldwide.
-
4Innovative Platforms
-
80 %R&D Employees
-
78Patents and patent applications
(of which 33 have been issued, and 45 applications are pending)
Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively.He also got a Doctor of Philosophy from McMaster University in November 2005.
Dr. Zhou has over 30 years of experience in the healthcare and pharmaceutical industries, he worked for a number of leading enterprise, including Schering-Plough Corporation, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.
Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology as well as a visiting professor at Central South University.
Dr. Yang Bin currently serves as the vice president of the manufacturing center of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).
Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.
-
Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively.He also got a Doctor of Philosophy from McMaster University in November 2005.
Dr. Zhou has over 30 years of experience in the healthcare and pharmaceutical industries, he worked for a number of leading enterprise, including Schering-Plough Corporation, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.
Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology as well as a visiting professor at Central South University.
-
Dr. Yang Bin currently serves as the vice president of the manufacturing center of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).
Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.
The predecessor of the Company, Wuhan YZY Biopharma Limited Company was established.
The initiation of BsAb platform development
The initiation of M802 R&D
The filing of the PCT patent application “Bispecific antibody” for the protection of the YBODY® platform
Patent protection for our YBODY® platform in U.S. expanded to cover 35 targets.
M701 became the second BsAb to file IND application in China.
M701 received China’s second IND approval for self-developed bispecific antibody.
March 2018 The establishment of the Check-BODY platform
Patent issued for the protection of M802 in China.
Patent issued for the protection of our YBODY® platform in CD3 and HER2 targets in U.S.
The establishment of the Nano-YBODY™ platform
Completed Series B Financing(1) and raised an aggregate amount of approximately RMB168.7 million.
Obtained NMPA IND approval for our clinical investigation of Y150 in rrMM in China.
Obtained FDA IND approval for our clinical investigation of Y101D for solid tumors in U.S.
Obtained NMPA IND approval for our clinical investigation of Y2019 in China
Initiated a Phase II clinical trial for M701 monotherapy in combination with systematic treatment for MA in patients with EpCAM-positive carcinomas in China.
The Company was converted into a joint stock limited company with its name changed to “Wuhan YZY Biopharma Co., Ltd.（武汉友芝友生物制药股份有限公司）
Obtained IND approval for a Phase Ib/II clinical trial of M701 for the treatment of MPE in China.
Entered into asset transfer agreement with CMS Vision for Y400.
Obtained the IND approval for a Phase Ib/II clinical trial of Y101D in combination with gemcitabine and albumin paclitaxel as the first-line treatment for pancreatic cancer patients in China
Obtained IND approval for a Phase Ib/II clinical trial of Y101D in combination with bevacizumab in treating HCC and other advanced solid tumors in China
Y332 received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA)
Y400 received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA)
-
Phone：027-82668988 -
E-Mail：info@yzybio.com -
Postcode：430075 -
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China -
Fax：027-68788819 -
Business Development Contact：wangjing@yzybio.com chenling@yzybio.com
E-Mail：info@yzybio.com
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
